Trial · NCT07541833
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 26 of 26
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Number of treatment emergent adverse events (TEAEs)/adverse drug reactions (ADRs) and serious TEAEs/ADRs | Up to week 16 | |
| Secondary | Proportion of participants continuing cibenzoline | Baseline and weeks 4, 8, 12, and 16 | |
| Secondary | Proportion of patients who decrease or increase dose and/or frequency of cibenzoline, beta blocker, or calcium channel blocker | Baseline and weeks 4, 8, 12, and 16 | |
| Secondary | Daily dose of cibenzoline, beta blocker, or calcium channel blocker | Baseline and weeks 4, 8, 12, and 16 | |
| Secondary | Change in Left Ventricular Ejection Fraction (LVEF) as assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 | |
| Secondary | Change in left ventricular stroke volume (LVSV) from baseline assessed by transthoracic echocardiography (TTE) | Baseline and up to week 16 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07541833/registered?page=2